Keywords: Ulcerative Colitis; Proctitis; Tacrolimus; Blinded Randomized Clinical Trial; CD; Crohn's disease; IBDQ; Inflammatory Bowel Disease Questionnaire; QOL; quality of life; TNF; tumor necrosis factor; UC; ulcerative colitis;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Disease Activity; Self-monitoring; Golimumab; PURSUIT; CCR; continuous clinical response; CRP; C-reactive protein; IBD; inflammatory bowel disease; IBDQ; inflammatory bowel disease questionnaire; PGA; physician global assessment; PROMIS; Patient Reported
Keywords: Chronic refractory pouchitis; Oral beclomethasone dipropionate; PDAI; IBDQ;
Keywords: SE; sequential capsule endoscopy; CD; Crohn's disease; SB; small bowel; CDAI; Crohn's Disease Activity Index; IBDQ; Inflammatory Bowel Disease Questionnaire; SICUS; small intestinal contrast ultrasonography; Capsule endoscopy; Crohn's disease; Sequential
Keywords: CD; Crohn's disease; CDAI; Crohn's disease activity index; IBD-DI; Inflammatory bowel disease disability index; IBDQ; Inflammatory Bowel Disease Questionnaire; ICF; International Classification of Functioning, Disability and Health; pMayo; partial Mayo sc
Keywords: IBD; Disability; WHODAS2; QoL; BSI; Brief Symptom Inventory; CD; Crohn's disease; CI; confidence interval; CIDI; Comprehensive International Diagnostic Interview; CPSS; Cohen Perceived Stress Scale; IBD; inflammatory bowel disease; IBDQ; Inflammatory Bo
Keywords: ANCOVA; analysis of covariance; ANOVA; analysis of variance; BFI; Big Five Inventory; CAI; Clinical Activity Index; CD; Crohn's disease; FC; faecal calprotectin; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IBDQ; Inflammat
Keywords: AZTEC Study; Inflammatory Bowel Diseases; Treatment; Corticosteroids; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; CI; confidence interval; CRP; C-reactive protein; IBDQ; Inflammatory Bowel Disease Questionnaire; RR; relative risk;
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease
Keywords: Combined Remission; Clinical Remission; Anal Fistula; Cell Therapy; CDAI; Crohn's Disease Activity Index; CI; confidence interval; Cx601; allogeneic; expanded; adipose-derived stem cells; IBDQ; inflammatory bowel disease questionnaire; LOCF; last observ
Original articleAlimentary tractAdalimumab for the Treatment of Japanese Patients With Intestinal Behçet's Disease
Keywords: Autoimmunity; Anti-TNF Agent; Endoscopy; Japan; AAA; anti-adalimumab antibodies; ADA; adalimumab; AE; adverse event; BD; Behçet's disease; CD; Crohn's disease; CRP; C-reactive protein; eow; every other week; GI; gastrointestinal; IBDQ; Intestinal Bow
TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial
Keywords: CSQ-8; Client Satisfaction Questionnaire; CCFA; Crohn's and Colitis Foundation of America; CCKNOW; Crohn's and Colitis Knowledge Score; CD; Crohn's disease; CDAI; Crohn's disease activity index; DSMB; Data Safety and Monitoring Board; EIMs; extraintestina
A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy
Keywords: Cellular Therapy; Intestine; Inflammation; Immune Response; Autoimmune; AQoL; assessment of quality of life; CD; Crohn's disease; CDAI; Crohn's disease activity index; CDEIS; Crohn's disease endoscopic index of severity; CMV; cytomegalovirus; CRP; C-react
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
Keywords: Tofacitinib; CP-690,550; Crohn's Disease; Randomized Control Trial; AE; adverse event; ANC; absolute neutrophil count; CDAI; Crohn's Disease Activity Index; CI; confidence interval; CRP; C-reactive protein; HDL; high-density lipoprotein; IBDQ; Inflamm
Original ResearchFull Report: Clinical-Alimentary TractCombination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Keywords: Tumor Necrosis Factor Inhibitors; Purine Antimetabolites; Biologic Treatment; AEs; adverse events; ATI; antibodies to infliximab; AZA; azathioprine; CI; confidence interval; CS; corticosteroid; IBDQ; Inflammatory Bowel Disease Questionnaire; IFX; inflixim
Original ResearchFull Report: Clinical-Alimentary TractEarly Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial
Keywords: Inflammatory Bowel Disease; IBD; Comparison of Treatment Strategies; Drug; CD; Crohn's disease; CDAI; Crohn's Disease Activity Index; IBDQ; Inflammatory Bowel Disease Questionnaire; IQR; interquartile range; TNF; tumor necrosis factor;
Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease
Keywords: Intravenous Iron; Crohn's Disease; Ulcerative Colitis; Iron Maintenance Treatment; AE; adverse events; CI; confidence interval; FAS; full analysis set; FCM; ferric carboxymaltose; Hb; hemoglobin; IBD; inflammatory bowel disease; IBDQ; inflammatory bowel d
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Keywords: Antibody Targeted Therapy; IBD; Clinical Trial Result; Inflammation; Colon; EOW; every other week; IBDQ; Inflammatory Bowel Disease Questionnaire; NNT; number needed to treat; TNF; tumor necrosis factor; UC; ulcerative colitis; ULTRA 1; ulcerative colitis
Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease
Keywords: Clinical Trial; Immunotherapy; Type 1 Treg; Inflammatory Bowel Disease; AE; adverse event; CDAI; Crohn Disease Activity Index; CRP; C-reactive protein; IBDQ; Inflammatory Bowel Disease Questionnaire; IL; interleukin; ITT; intention-to-treat; LOCF; last ob
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Keywords: CD; Crohn's disease; PPD; purified protein derivative; TPN; total parenteral nutrition; CDAI; CD activity index; CR-70; decrease in CDAI score from Baseline â¥Â 70; CR-100; decrease in CDAI score from Baseline â¥Â 100; eow; every other week; 6-MP; 6-m
Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease
Keywords: CHD; coronary heart disease; CD; Crohn's disease; HRQoL; health-related quality of life; IBD; inflammatory bowel disease; IBDQ; Inflammatory Bowel Disease Questionnaire; IC; indeterminate/unspecified colitis; SD; standard deviation; UC; ulcerative colitis
FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease
Keywords: Intravenous Iron; Crohn's Disease; Ulcerative Colitis; CI; confidence interval; FCM; ferric carboxymaltose; Hb; hemoglobin; IBDQ; inflammatory bowel disease questionnaire; IDA; iron deficiency anemia; IS; iron sucrose; OR; odds ratio; SF-36; health survey
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Keywords: Biologic; Inflammatory Bowel Disease; Inflammatory Burden; CDAI; Crohn's Disease Activity Index; CRP; C-reactive protein; GCP; good clinical practices; HBI; Harvey-Bradshaw Index; HRQoL; health-related quality of life; IBDQ; Inflammatory Bowel Disease Q
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
Keywords: Crohn's Disease; Anti-TNF; Certolizumab Pegol; CDAI; Crohn's Disease Activity Index; CRP; C-reactive protein; IBDQ; Inflammatory Bowel Disease Questionnaire; TNF-α; tumor necrosis factor-α;
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Keywords: AE; adverse event; CDAI; Crohn's Disease Activity Index; HAHA; human anti-human antibodies; IBD; inflammatory bowel disease; IBDQ; Inflammatory Bowel Disease Questionnaire; PML; progressive multifocal leukoencephalopathy; SAE; serious adverse events;
Intravenous iron therapy restores functional iron deficiency induced by infliximab
Keywords: CDAI; Crohn's Disease Activity Index; CD; Crohn's disease; CRP; C-reactive protein; EPO; Erythropoietin; FeS; I.V. iron sucrose; Hb; Haemoglobin; IBD; Inflammatory Bowel Disease; IBDQ; Inflammatory Bowel Disease Questionnaire; IDRA; Iron deficiency relate
Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial
Keywords: AE; adverse event; CRP; C-reactive protein; IBDQ; Inflammatory Bowel Disease Questionnaire; PML; progressive multifocal leukoencephalopathy; SF-36; Short Form-36; ULN; upper limit of normal;
Coping Strategies and Interpersonal Support in Patients With Irritable Bowel Syndrome and Inflammatory Bowel Disease
Keywords: ANOVA; analysis of variance; IBD; inflammatory bowel disease; IBDQ; Inflammatory Bowel Disease Questionnaire; IBS; irritable bowel syndrome; QOL; quality of life; SCL-90-R; Symptom Checklist-90-revised; TAS-20; 20-item Toronto Alexithymia Scale; WOC; Ways
The Relationship of Inflammatory Bowel Disease Type and Activity to Psychological Functioning and Quality of Life
Keywords: CD; Crohn's disease; IBD; inflammatory bowel disease; IBDQ; Inflammatory Bowel Disease Questionnaire; QOL; Quality of life; SF-36; Medical Outcomes Study 36-item Short Form Questionnaire; UC; ulcerative colitis;
Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease
Keywords: BMD; bone mineral density; CR; controlled release; DXA; dual-energy x-ray absorptiometry; IBDQ; Inflammatory Bowel Disease Questionnaire; SF-36; Short Form 36 questionnaire;
A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease
Keywords: AE; adverse event; CI; confidence interval; CRP; C-reactive protein; IBDQ; Inflammatory Bowel Disease Questionnaire; ITT; intent to treat; TNF; tumor necrosis factor;
Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations
Keywords: AO; aldehyde oxidase; AZA; azathioprine; CD; Crohn's disease; DNA; deoxynucleic acid; FDA; Food and Drug Administration; GMPS; guanosine monophosphate synthetase; HPRT; hypoxanthine phosphoribosyl transferase; IBD; inflammatory bowel disease; IBDQ; Inflam